Publikationen 2023

Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms. Holl K, Chatain N, Krapp S, Baumeister J, Maié T, Schmitz S, Scheufen A, Brock N, Koschmieder S, Moreno-Andrés D. Sci Rep. 2024 Feb 2;14(1):2810. doi: 10.1038/s41598-024-53240-8. PMID: 38308077 Free PMC article.
Proinflammatory phenotype of iPS cell-derived JAK2 V617F megakaryocytes induces fibrosis in 3D in vitro bone marrow niche. Flosdorf N, Böhnke J, de Toledo MAS, Lutterbach N, Lerma VG, Graßhoff M, Olschok K, Gupta S, Tharmapalan V, Schmitz S, Götz K, Schüler HM, Maurer A, Sontag S, Küstermann C, Seré K, Wagner W, Costa IG, Brümmendorf TH, Koschmieder S, Chatain N, Castilho M, Schneider RK, Zenke M. Stem Cell Reports. 2024 Jan 8:S2213-6711(23)00504-0. doi: 10.1016/j.stemcr.2023.12.011. Online ahead of print. PMID: 38278152 Free article.
Exploiting Synthetic Lethality between Germline BRCA1 Haploinsufficiency and PARP Inhibition in JAK2V617F-Positive Myeloproliferative Neoplasms. Bermes M, Rodriguez MJ, de Toledo MAS, Ernst S, Müller-Newen G, Brümmendorf TH, Chatain N, Koschmieder S, Baumeister J. Int J Mol Sci. 2023 Dec 16;24(24):17560. doi: 10.3390/ijms242417560. PMID: 38139386 Free PMC article.
Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. Pritchard JE, Pearce JE, Snoeren IAM, Fuchs SNR, Götz K, Peisker F, Wagner S, Benabid A, Lutterbach N, Klöker V, Nagai JS, Hannani MT, Galyga AK, Sistemich E, Banjanin B, Flosdorf N, Bindels E, Olschok K, Biaesch K, Chatain N, Bhagwat N, Dunbar A, Sarkis R, Naveiras O, Berres ML, Koschmieder S, Levine RL, Costa IG, Gleitz HFE, Kramann R, Schneider RK. Cell Rep. 2024 Jan 23;43(1):113608. doi: 10.1016/j.celrep.2023.113608. Epub 2023 Dec 20. PMID: 38117649 Free PMC article.
A newly identified 45-kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance. Gorantla SP, Mueller TA, Albers-Leischner C, Rudelius M, von Bubnoff N, Duyster J. Mol Oncol. 2024 Feb;18(2):415-430. doi: 10.1002/1878-0261.13566. Epub 2023 Dec 20. PMID: 38104968 Free PMC article.
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4. PMID: 38061384 Review.
The telomerase inhibitor imetelstat differentially targets JAK2V617F versus CALR mutant myeloproliferative neoplasm cells and inhibits JAK-STAT signaling. Olschok K, Altenburg B, de Toledo MAS, Maurer A, Abels A, Beier F, Gezer D, Isfort S, Paeschke K, Brümmendorf TH, Zenke M, Chatain N, Koschmieder S. Front Oncol. 2023 Oct 24;13:1277453. doi: 10.3389/fonc.2023.1277453. eCollection 2023. PMID: 37941547 Free PMC article.
Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms. Vieri M, Tharmapalan V, Kalmer M, Baumeister J, Nikolić M, Schnitker M, Kirschner M, Flosdorf N, de Toledo MAS, Zenke M, Koschmieder S, Brümmendorf TH, Beier F, Wagner W. Blood Cancer J. 2023 Nov 6;13(1):164. doi: 10.1038/s41408-023-00936-1. PMID: 37926720 Free PMC article. No abstract available.
Detection of a rare JAK2exon13InDel-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Löffler endocarditis. Eisenach S, Zinke J, Brämer D, Hartinger S, Haferlach T, Kreipe HH, Hammersen J, Hamadanchi A, Otto S, Schulze PC, Bürckenmeyer F, Teichgräber U, Hochhaus A, Witte OW, Günther A, Schrenk KG. Ann Hematol. 2024 Jan;103(1):363-365. doi: 10.1007/s00277-023-05490-1. Epub 2023 Oct 16. PMID: 37843619 Free PMC article. No abstract available.
Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms. Wille K, Deventer E, Sadjadian P, Becker T, Kolatzki V, Hünerbein K, Meixner R, Jiménez-Muñoz M, Fuchs C, Griesshammer M. Hamostaseologie. 2023 Oct 9. doi: 10.1055/a-2159-8767. Online ahead of print. PMID: 37813367 Free article.
Validation of myeloproliferative neoplasms associated risk factor RDW as predictor of thromboembolic complications in healthy individuals: analysis on 6849 participants of the SHIP-study. Manz K, Bahr J, Ittermann T, Döhner K, Koschmieder S, Brümmendorf TH, Griesshammer M, Nauck M, Völzke H, Heidel FH. Leukemia. 2023 Aug;37(8):1745-1749. doi: 10.1038/s41375-023-01943-8. Epub 2023 Jun 23. PMID: 37353711 Free PMC article. No abstract available.
Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany. Schmidt A, Bernhardt C, Bürkle D, Fries S, Hannig CV, Jentsch-Ullrich K, Josting A, Kreher S, Reiser M, Steinmetz HT, Tesch H, Terner S, Schulte A, Crodel CC, Palandri F, Heidel FH. J Cancer Res Clin Oncol. 2023 Aug;149(10):7197-7206. doi: 10.1007/s00432-023-04669-3. Epub 2023 Mar 8. PMID: 36884118 Free PMC article.
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study. Palandri F, Rossi E, Auteri G, Breccia M, Paglia S, Benevolo G, Elli EM, Cavazzini F, Binotto G, Tieghi A, Tiribelli M, Heidel FH, Bonifacio M, Pugliese N, Caocci G, Crugnola M, Mendicino F, D'Addio A, Tomassetti S, Martino B, Polverelli N, Ceglie S, Mazzoni C, Mullai R, Ripamonti A, Garibaldi B, Pane F, Cuneo A, Krampera M, Semenzato G, Lemoli RM, Vianelli N, Palumbo GA, Andriani A, Cavo M, Latagliata R, De Stefano V. Cancers (Basel). 2023 Jul 21;15(14):3706. doi: 10.3390/cancers15143706. PMID: 37509367 Free PMC article.
Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms. Hinze A, Rinke J, Crodel CC, Möbius S, Schäfer V, Heidel FH, Hochhaus A, Ernst T. Br J Haematol. 2023 Jul;202(2):308-317. doi: 10.1111/bjh.18834. Epub 2023 May 4. PMID: 37139709
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome. Palandri F, Breccia M, Mazzoni C, Auteri G, Elli EM, Trawinska MM, Polverelli N, Tiribelli M, Benevolo G, Iurlo A, Tieghi A, Heidel FH, Caocci G, Beggiato E, Binotto G, Cavazzini F, Miglino M, Bosi C, Crugnola M, Bocchia M, Martino B, Pugliese N, Biondo M, Venturi M, Scaffidi L, Isession_id()ori A, Cattaneo D, Krampera M, Pane F, Cilloni D, Semenzato G, Lemoli RM, Cuneo A, Abruzzese E, Bartoletti D, Paglia S, Vianelli N, Cavo M, Bonifacio M, Palumbo GA. Cancer. 2023 Jun 1;129(11):1704-1713. doi: 10.1002/cncr.34722. Epub 2023 Mar 18. PMID: 36932983 Free article.
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib. Palandri F, Elli EM, Auteri G, Bonifacio M, Benevolo G, Heidel FH, Paglia S, Trawinska MM, Bosi C, Rossi E, Tiribelli M, Tieghi A, Iurlo A, Polverelli N, Caocci G, Binotto G, Cavazzini F, Beggiato E, Cilloni D, Tatarelli C, Mendicino F, Miglino M, Bocchia M, Crugnola M, Mazzoni C, Romagnoli AD, Rindone G, Ceglie S, D'Addio A, Santoni E, Cattaneo D, Bartoletti D, Lemoli RM, Krampera M, Cuneo A, Semenzato GC, Latagliata R, Abruzzese E, Vianelli N, Cavo M, Andriani A, De Stefano V, Palumbo GA, Breccia M. Blood Cancer J. 2023 May 3;13(1):65. doi: 10.1038/s41408-023-00834-6. PMID: 37137878 Free PMC article. No abstract available.
Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. PMID: 36564535 Free PMC article. Clinical Trial.
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Stegelmann F, Teichmann LL, Heidel FH, Crodel CC, Ernst T, Kreil S, Reiter A, Otten S, Schauer S, Körber RM, Kricheldorf K, Isfort S, Döhner H, Brümmendorf TH, Griesshammer M, Döhner K, Koschmieder S. Leukemia. 2023 Apr;37(4):924-928. doi: 10.1038/s41375-023-01837-9. Epub 2023 Feb 24. PMID: 36828867; PMCID: PMC10079540
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial. Koschmieder S, Isfort S, Schulte C, Jacobasch L, Geer T, Reiser M, Koenigsmann M, Heinrich B, Wehmeyer J, von der Heyde E, Tesch H, Gröschl B, Bachhuber P, Großer S, Pahl HL. Ann Hematol. 2023 Dec;102(12):3383-3399. doi: 10.1007/s00277-023-05458-1. Epub 2023 Oct 4. PMID: 37792065; PMCID: PMC10640411.

Publikationen 2022

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nałęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Am J Hematol. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. Epub 2022 Sep 27. PMID: 36111658 Free PMC article. No abstract available.
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis. Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, Scott BL, Woszczyk D, Koschmieder S, García-Delgado R, László R, McGreivy JS, Rothbaum WP, Kiladjian JJ. Future Oncol. 2022 Nov 23. doi: 10.2217/fon-2022-0901. Online ahead of print. PMID: 36416118 Free article. Review.
Breakthrough infections in MPN-COVID vaccinated patients. Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Blood Cancer J. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921 Free PMC article. No abstract available.
Mast cells as a therapeutic target in myeloproliferative neoplasms. Toledo MAS, Chatain N, Zenke M, Koschmieder S. Trends Mol Med. 2022 Nov;28(11):902-905. doi: 10.1016/j.molmed.2022.08.008. Epub 2022 Sep 2. PMID: 36064534
Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis. Perram J, Ross DM, McLornan D, Gowin K, Kröger N, Gupta V, Lewis C, Gagelmann N, Hamad N. Am J Hematol. 2022 Nov;97(11):1464-1477. doi: 10.1002/ajh.26654. Epub 2022 Jul 19. PMID: 35802782 Free PMC article. Review.
Clonogenic assays improve determination of variant allele frequency of driver mutations in myeloproliferative neoplasms. Kalmer M, Pannen K, Lemanzyk R, Wirths C, Baumeister J, Maurer A, Kricheldorf K, Schifflers J, Gezer D, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N. Ann Hematol. 2022 Dec;101(12):2655-2663. doi: 10.1007/s00277-022-05000-9. Epub 2022 Oct 21. PMID: 36269400; PMCID: PMC9646600.
German Study Group for Myeloproliferative Neoplasms (GSG-MPN). Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, Jost PJ, Parmentier S, Schaich M, von Bubnoff N, Stegelmann F, Maurer A, Crysandt M, Gezer D, Kortmann M, Franklin J, Frank J, Hellmich M, Brümmendorf TH; Ann Hematol. 2023 Feb;102(2):349-358. doi: 10.1007/s00277-022-05080-7. Epub 2022 Dec 23. PMID: 36564535; PMCID: PMC9889492.
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera. Crodel CC, Jentsch-Ullrich K, Reiser M, Jacobasch L, Sauer A, Tesch H, Ulshöfer T, Wunschel R, Palandri F, Heidel FH. J Cancer Res Clin Oncol. 2022 Oct;148(10):2693-2705. doi: 10.1007/s00432-021-03855-5. Epub 2021 Nov 22. PMID: 34807311 Free PMC article.
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. O'Hagan Henderson S, Frietsch JJ, Hilgendorf I, Hochhaus A, Köhne CH, Casper J. J Cancer Res Clin Oncol. 2022 Oct;148(10):2599-2609. doi: 10.1007/s00432-021-03836-8. Epub 2021 Oct 21. PMID: 34674031 Free PMC article.
Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. Sobas M, Kiladjian JJ, Beauverd Y, Curto-Garcia N, Sadjadian P, Shih LY, Devos T, Krochmalczyk D, Galli S, Bieniaszewska M, Seferynska I, McMullin MF, Armatys A, Spalek A, Waclaw J, Zdrenghea M, Legros L, Girodon F, Lewandowski K, Angona Figueras A, Samuelsson J, Abuin Blanco A, Cony-Makhoul P, Collins A, James C, Kusec R, Lauermannova M, Noya MS, Skowronek M, Szukalski L, Szmigielska-Kaplon A, Wondergem M, Dudchenko I, Gora Tybor J, Laribi K, Kulikowska de Nalecz A, Demory JL, Le Du K, Zweegman S, Besses Raebel C, Skoda R, Giraudier S, Griesshammer M, Harrison CN, Ianotto JC. Blood Adv. 2022 Sep 13;6(17):5171-5183. doi: 10.1182/bloodadvances.2022007201. PMID: 35802458 Free PMC article.
Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms. Ibarra J, Elbanna YA, Kurylowicz K, Ciboddo M, Greenbaum HS, Arellano NS, Rodriguez D, Evers M, Bock-Hughes A, Liu C, Smith Q, Lutze J, Baumeister J, Kalmer M, Olschok K, Nicholson B, Silva D, Maxwell L, Dowgielewicz J, Rumi E, Pietra D, Casetti IC, Catricala S, Koschmieder S, Gurbuxani S, Schneider RK, Oakes SA, Elf SE. Blood Cancer Discov. 2022 Jul 6;3(4):298-315. doi: 10.1158/2643-3230.BCD-21-0144. PMID: 35405004 Free PMC article.
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study. Passamonti F, Palandri F, Saydam G, Callum J, Devos T, Guglielmelli P, Vannucchi AM, Zor E, Zuurman M, Gilotti G, Zhang Y, Griesshammer M. Lancet Haematol. 2022 Jul;9(7):e480-e492. doi: 10.1016/S2352-3026(22)00102-8. Epub 2022 May 18. PMID: 35597252 Clinical Trial.
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Álvarez-Larrán A, De Stefano V, Guglielmelli P, Palandri F, Passamonti F, Barosi G, Silver RT, Hehlmann R, Kiladjian JJ, Barbui T. Lancet Haematol. 2022 Apr;9(4):e301-e311. doi: 10.1016/S2352-3026(22)00046-1. PMID: 35358444 Review.
Thromboinflammation in Myeloproliferative Neoplasms (MPN)-A Puzzle Still to Be Solved. Bhuria V, Baldauf CK, Schraven B, Fischer T. Int J Mol Sci. 2022 Mar 16;23(6):3206. doi: 10.3390/ijms23063206. PMID: 35328626 Free PMC article. Review.
[What's new in myeloproliferative neoplasia?]. Schmidt S, Wolf D. Dtsch Med Wochenschr. 2022 Mar;147(6):306-311. doi: 10.1055/a-1643-4357. Epub 2022 Mar 15. PMID: 35291035 German.
Second versus first wave of COVID-19 in patients with MPN. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, Patriarca A, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nałęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Leukemia. 2022 Mar;36(3):897-900. doi: 10.1038/s41375-022-01507-2. Epub 2022 Jan 21. PMID: 35064223 Free PMC article. No abstract available.
Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients. Wille K, Huenerbein K, Jagenberg E, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, Griesshammer M. Eur J Haematol. 2022 Feb;108(2):154-162. doi: 10.1111/ejh.13721. Epub 2021 Nov 10. PMID: 34719056

Publikationen 2021

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B, Ferrer Marín F, Vannucchi AM, Palandri F, Harrison C, Sibai H, Griesshammer M, Bonifacio M, Elli EM, Trotti C, Koschmieder S, Carli G, Benevolo G, Ianotto JC, Goel S, Falanga A, Betti S, Cattaneo D, Arellano-Rodrigo E, Mannelli L, Vianelli N, Doyle A, Gupta V, Wille K, Tremblay D, Mascarenhas J. Leukemia. 2021 Oct;35(10):2989-2993.
Anti-inflammatory treatment in MPN: Targeting TNFα-receptor 1 (TNFR1) and TNFR2 in JAK2-V617F induced disease. Müller P, Baldauf CK, Haage TR, Waldleben AM, Richter F, Pfizenmaier K, Fischer T. Blood Adv. 2021 Sep 30:bloodadvances.2021004438. doi: 10.1182/bloodadvances.2021004438. Epub ahead of print. PMID: 34592754.
Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Schmidt S, Daniliants D, Hiller E, Gunsilius E, Wolf D, Feistritzer C. Blood Adv. 2021 Sep 28;5(18):3515-3527.
Anti-IL-6 cytokine treatment has no impact on elevated hematocrit and splenomegaly in a polycythemia vera mouse model. Baldauf CK, Müller P, Haage TR, Adam-Frey S, Lokau J, Garbers C, Fischer T. Blood Adv. 2021 Sep 24:bloodadvances.2021004379. doi: 10.1182/bloodadvances.2021004379. Epub ahead of print. PMID: 34559181.
Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms. Elbracht M, Meyer R, Kricheldorf K, Gezer D, Thomas E, Betz B, Kurth I, Teichmann LL, Brümmendorf TH, Germing U, Isfort S, Koschmieder S. Blood Adv. 2021 Sep 14;5(17):3373-3376.
The EHA Research Roadmap: Malignant Myeloid Diseases. Döhner H, Malcovati L, Ossenkoppele GJ, Hochhaus A, Maria Vannucchi A, Bullinger L, Cervantes F, Craddock C, de Witte T, Döhner K, Dombret H, Fenaux P, Geissler J, Germing U, Guilhot F, Harrison C, Hellström-Lindberg E, Passamonti F, Sierra J, Skoda R, Wierzbowska A. Hemasphere. 2021 Aug 26;5(9):e635.
The incidental discovery of a constitutional trisomy 21 mosaicism in an adult female with myelodysplastic/myeloproliferative neoplasm. O'Hagan Henderson S, Glaser A, Frietsch JJ, Hochhaus A, Hilgendorf I. Ann Hematol. 2021 Sep 1. doi: 10.1007/s00277-021-04655-0. Epub ahead of print. PMID: 34471943.
Unmet clinical needs in the management of CALR- mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Alvarez-Larrán A, Sant'Antonio E, Harrison C, Kiladjian JJ, Griesshammer M, Mesa R, Ianotto JC, Palandri F, Hernández-Boluda JC, Birgegård G, Nangalia J, Koschmieder S, Rumi E, Barbui T. Lancet Haematol. 2021 Sep;8(9):e658-e665.
NK Cells in Myeloproliferative Neoplasms (MPN). Naismith E, Steichen J, Sopper S, Wolf D. Cancers (Basel). 2021 Aug 31;13(17):4400.
The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN. Tillmann S, Olschok K, Schröder SK, Bütow M, Baumeister J, Kalmer M, Preußger V, Weinbergerova B, Kricheldorf K, Mayer J, Kubesova B, Racil Z, Wessiepe M, Eschweiler J, Isfort S, Brümmendorf TH, Becker W, Schemionek M, Weiskirchen R, Koschmieder S, Chatain N. Cancers (Basel). 2021 Aug 21;13(16):4210.
Early and late stage MPN patients show distinct gene expression profiles in CD34 + cells Baumeister J, Maié T, Chatain N, Gan L, Weinbergerova B, de Toledo MAS, Eschweiler J, Maurer A, Mayer J, Kubesova B, Racil Z, Schuppert A, Costa I, Koschmieder S, Brümmendorf TH, Gezer D. Ann Hematol. 2021 Aug 14. doi: 10.1007/s00277-021-04615-8. Epub ahead of print. PMID: 34390367.
Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. Gecht J, Tsoukakis I, Kricheldorf K, Stegelmann F, Klausmann M, Griesshammer M, Schulz H, Hollburg W, Göthert JR, Sockel K, Heidel FH, Gattermann N, Maintz C, Al-Ali HK, Platzbecker U, Hansen R, Hänel M, Parmentier S, Bommer M, Pahl HL, Lang F, Kirschner M, Isfort S, Brümmendorf TH, Döhner K, Koschmieder S. Cancers (Basel). 2021 Aug 13;13(16):4086.
Pacritinib protects dendritic cells more efficiently than ruxolitinib. Heine A, Wolf AM, Schlaweck S, Daecke SN, Brossart P, Wolf D. Exp Hematol. 2021 Aug;100:37-40.
Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE/VTE) in myeloproliferative neoplasms. Huenerbein K, Sadjadian P, Becker T, Kolatzki V, Deventer E, Engelhardt C, Griesshammer M, Wille K. Ann Hematol. 2021 Aug;100(8):2015-2022.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. Passamonti F, Gupta V, Martino B, Foltz L, Zaritskey A, Al-Ali HK, Tavares R, Maffioli M, Raanani P, Giraldo P, Griesshammer M, Guglielmelli P, Bouard C, Paley C, Tiwari R, Vannucchi AM. Hematol Oncol. 2021 Jul 5.
A review of hydroxyurea-related cutaneous adverse events. Griesshammer M, Wille K, Sadjadian P, Stegelmann F, Döhner K. Expert Opin Drug Saf. 2021 Jun 28:1-7.
Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN. Kricheldorf K, Döhner K, Stegelmann F, Jost PJ, Lang F, Radsak M, Hansen R, Heuer V, Röhrig R, Brümmendorf TH, Koschmieder S, Isfort S. Leuk Res. 2021 Jun 16;110:106646.
Long-term follow-up of recovered MPN patients with COVID-19. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A, Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, Patriarca A, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Blood Cancer J. 2021 Jun 16;11(6):115.
JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality. Rao TN, Hansen N, Stetka J, Luque Paz D, Kalmer M, Hilfiker J, Endele M, Ahmed N, Kubovcakova L, Rybarikova M, Hao-Shen H, Geier F, Beisel C, Dirnhofer S, Schroeder T, Brümmendorf TH, Wolf D, Koschmieder S, Skoda RC. Blood. 2021 Apr 22;137(16):2139-2151.
Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, Stalmann USA, Büsche G, Kreipe H, Gütgemann I, Krebs P, Banz Y, Boor P, Tai EW, Brümmendorf TH, Koschmieder S, Crysandt M, Bindels E, Kramann R, Costa IG, Schneider RK. Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8.
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study. Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Leuk Lymphoma. 2021 Apr;62(4):918-926.
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Rambaldi A, Iurlo A, Vannucchi AM, Martino B, Guarini A, Ruggeri M, von Bubnoff N, De Muro M, McMullin MF, Luciani S, Martinelli V, Nogai A, Rosti V, Ricco A, Bettica P, Manzoni S, Di Tollo S. Blood Cancer J. 2021 Mar 6;11(3):53.
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With CALR-Mutant Chronic Myeloproliferative Neoplasms. Handlos Grauslund J, Holmström MO, Jørgensen NG, Klausen U, Weis-Banke SE, El Fassi D, Schöllkopf C, Clausen MB, Gjerdrum LMR, Breinholt MF, Kjeldsen JW, Hansen M, Koschmieder S, Chatain N, Novotny GW, Petersen J, Kjær L, Skov V, Met Ö, Svane IM, Hasselbalch HC, Andersen MH. Front Oncol. 2021 Feb 26;11:637420.
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Blood Cancer J. 2021 Feb 4;11(2):21.
Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. Ernst P, Heidel FH. Cancers (Basel). 2021 Feb 4;13(4):612.
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, Patriarca A, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. Leukemia. 2021 Feb;35(2):485-493.
A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs. Schnoeder TM, Perner F, Heidel FH. Mol Cell Oncol. 2021 Jan 30;8(2):1871172.
Austrian recommendations for the management of essential thrombocythemia. Buxhofer-Ausch V, Heibl S, Sliwa T, Beham-Schmid C, Wolf D, Geissler K, Krauth MT, Krippl P, Petzer A, Wölfler A, Melchardt T, Gisslinger H. Wien Klin Wochenschr. 2021 Jan;133(1-2):52-61.
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion- dependence and correlate with response to pomalidomide. Chowdhury O, O'Sullivan J, Barkas N, Wang G, Buck G, Hamblin A, Tefferi A, Al-Ali HK, Barosi G, Devos T, Gisslinger H, Jiang Q, Kiladjian JJ, Mesa R, Passamonti F, Ribrag V, Schiller G, Vannucchi AM, Zhou D, McMullin MF, Zhong J, Gale RP, Mead AJ; RESUME trialists. Leukemia. 2021 Apr;35(4):1197-1202.
Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Stegelmann F, Wille K, Busen H, Fuchs C, Schauer S, Sadjadian P, Becker T, Kolatzki V, Döhner H, Stadler R; German Study Group-MPN, Döhner K, Griesshammer M. Leukemia. 2021 Feb;35(2):628-631.
Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm. Molitor DCA, Boor P, Buness A, Schneider RK, Teichmann LL, Körber RM, Horvath GL, Koschmieder S, Gütgemann I. Ann Hematol. 2021 Jan;100(1):97-104.

Publikationen 2020

Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Leukemia. 2020 Nov;34(11):3106. doi: 10.1038/s41375-020-0970-2. Erratum for: Leukemia. 2020 Jul;34(7):1949-1953. PMID: 32651539; PMCID: PMC7962558.
German Study Group MPN, GSG-MPN. Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. Schrickel L, Heidel FH, Sadjadian P, Becker T, Kolatzki V, Hochhaus A, Griesshammer M, Wille K;. J Cancer Res Clin Oncol. 2021 May;147(5):1481-1491. doi: 10.1007/s00432-020-03430-4. Epub 2020 Nov 2. PMID: 33140210.
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Jayavelu AK, Schnöder TM, Perner F, Herzog C, Meiler A, Krishnamoorthy G, Huber N, Mohr J, Edelmann-Stephan B, Austin R, Brandt S, Palandri F, Schröder N, Isermann B, Edlich F, Sinha AU, Ungelenk M, Hübner CA, Zeiser R, Rahmig S, Waskow C, Coldham I, Ernst T, Hochhaus A, Jilg S, Jost PJ, Mullally A, Bullinger L, Mertens PR, Lane SW, Mann M, Heidel FH. Nature. 2020 Dec;588(7836):157-163.
Mutational mechanisms of EZH2 inactivation in myeloid neoplasms. Chase A, Score J, Lin F, Bryant C, Waghorn K, Yapp S, Carreno-Tarragona G, Aranaz P, Villasante A, Ernst T, Cross NCP. Leukemia. 2020 Dec;34(12):3206-3214.
EZH2 in Myeloid Malignancies. Rinke J, Chase A, Cross NCP, Hochhaus A, Ernst T. Cells. 2020 Jul 8;9(7):1639.
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Javorniczky NR, Wehrle J, Ihorst G, Hupfer V, Aumann K, Pfeifer D, Niemöller C, Bleul S, Pantic M, Werner M, Duyster J, Finke J, Engelhardt M, von Bubnoff N, Waller CF, Pahl HL, Becker H. Leuk Res. 2020 Sep 15;98:106454.
Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations. Sadjadian P, Wille K, Griesshammer M. Cancers (Basel). 2020 Oct 26;12(11):E3132.
Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms. Chatain N, Koschmieder S, Jost E. Cancers (Basel). 2020 Aug 12;12(8):E2250.
Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. Crodel CC, Jentsch-Ullrich K, Koschmieder S, Kämpfe D, Griesshammer M, Döhner K, Jost PJ, Wolleschak D, Isfort S, Stegelmann F, Jilg S, Hofmann V, Auteri G, Rachow T, Ernst P, Brioli A, von Lilienfeld-Toal M, Hochhaus A, Palandri F, Heidel FH. Leukemia. 2020 Jul;34(7):1949-1953. Erratum in: Leukemia. 2020 Jul 10;: PMID: 32474573; PMCID: PMC7261209.
Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, Frewin R, Jost PJ, Lichtenegger FS, La Rosée P, Storch N, Haferlach T, Horny HP, Fabarius A, Haferlach C, Burchert A, Hofmann WK, Cross NCP, Hochhaus A, Reiter A, Metzgeroth G. Am J Hematol. 2020 Jul;95(7):824-833.
Role of inflammation in the biology of myeloproliferative neoplasms. Koschmieder S, Chatain N. Blood Rev. 2020 Jul;42:100711
Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. Gupta V, Wolleschak D, Hasselbalch H, Vannucchi AM, Koschmieder S, Cervantes F, Li Y, Dong T, Wroclawska M, Bharathy S, Harrison C. Blood Adv. 2020 Jul 14;4(13):3063-3071.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Br J Haematol. 2020 Jun;189(5):888-903.
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Austin RJ, Straube J, Bruedigam C, Pali G, Jacquelin S, Vu T, Green J, Gräsel J, Lansink L, Cooper L, Lee SJ, Chen NT, Lee CW, Haque A, Heidel FH, D'Andrea R, Hill GR, Mullally A, Milsom MD, Bywater M, Lane SW.Leukemia. 2020 Apr;34(4):1075-1089.
Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms. Baumeister J, Chatain N, Hubrich A, Maié T, Costa IG, Denecke B, Han L, Küstermann C, Sontag S, Seré K, Strathmann K, Zenke M, Schuppert A, Brümmendorf TH, Kranc KR, Koschmieder S, Gezer D. Leukemia. 2020 Apr;34(4):1062-1074.
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin. Barbui T, Ghirardi A, Vannucchi AM, Marchetti M, De Stefano V; MPN-K authors. Leukemia. 2020 Apr;34(4):1208-1209.
Second cancers in MPN: survival analysis from an international study. Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Pane F, De Stefano V, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Am J Hematol. 2020 Mar;95(3):295-301.
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. Kiladjian JJ, Zachee P, Hino M, Pane F, Masszi T, Harrison CN, Mesa R, Miller CB, Passamonti F, Durrant S, Griesshammer M, Kirito K, Besses C, Moiraghi B, Rumi E, Rosti V, Blau IW, Francillard N, Dong T, Wroclawska M, Vannucchi AM, Verstovsek S. Lancet Haematol. 2020 Mar;7(3):e226-e237.
How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms. Koschmieder S. Hamostaseologie. 2020 Feb;40(1):47-53.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson CIM, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Blood. 2020 Jan 30;135(5):381-386.

Publikationen 2019

Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms. Kirschner M, Bornemann A, Schubert C, Gezer D, Kricheldorf K, Isfort S, Brümmendorf TH, Schemionek M, Chatain N, Skorski T, Koschmieder S. Ann Hematol. 2019 Dec;98(12):2703-2709.
JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Nageswara Rao T, Hansen N, Hilfiker J, Rai S, Majewska JM, Leković D, Gezer D, Andina N, Galli S, Cassel T, Geier F, Delezie J, Nienhold R, Hao-Shen H, Beisel C, Di Palma S, Dimeloe S, Trebicka J, Wolf D, Gassmann M, Fan TW, Lane AN, Handschin C, Dirnhofer S, Kröger N, Hess C, Radimerski T, Koschmieder S, Čokić VP, Skoda RC. Blood. 2019 Nov 21;134(21):1832-1846.
Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Perner F, Perner C, Ernst T, Heidel FH. Cells. 2019 Aug 8;8(8). Review.
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms. Mughal TI, Pemmaraju N, Radich JP, Deininger MW, Kucine N, Kiladjian JJ, Bose P, Gotlib J, Valent P, Chen CC, Barbui T, Rampal R, Verstovsek S, Koschmieder S, Saglio G, Van Etten RA. Hematol Oncol. 2019 Aug;37(3):240-252. Review.
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. Barbui T, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, Patriarca A, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Leukemia. 2019 Aug;33(8):1996-2005.
Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. Kresinsky A, Schnöder TM, Jacobsen ID, Rauner M, Hofbauer LC, Ast V, König R, Hoffmann B, Svensson CM, Figge MT, Hilger I, Heidel FH, Böhmer FD, Müller JP. Oncogene. 2019 Jun;38(24):4773-4787.
Thromboembolic events in polycythemia vera. Griesshammer M, Kiladjian JJ, Besses C. Ann Hematol. 2019 May;98(5):1071-1082.
JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Czech J, Cordua S, Weinbergerova B, Baumeister J, Crepcia A, Han L, Maié T, Costa IG, Denecke B, Maurer A, Schubert C, Feldberg K, Gezer D, Brümmendorf TH, Müller-Newen G, Mayer J, Racil Z, Kubesova B, Knudsen T, Sørensen AL, Holmström M, Kjær L, Skov V, Larsen TS, Hasselbalch HC, Chatain N, Koschmieder S. Leukemia. 2019 Apr;33(4):995-1010.
[Differential Diagnosis of Erythrocytosis - Background and Clinical Relevance]. Wille K, Sadjadian P, Griesshammer M. Dtsch Med Wochenschr. 2019 Jan;144(2):128-135. German.
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C, Griesshammer M. Ann Hematol. 2019 Jan;98(1):93-100.

Publikationen 2018

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, Baxter E, Heidecker M, Wackrow B, Porter A, Ling V, Green J, Austin R, Kazakoff S, Waddell N, Hesson LB, Pimanda JE, Stegelmann F, Bullinger L, Döhner K, Rampal RK, Heckl D, et al.; Blood. 2018 Dec 27;132(26):2707-2721. Epub 2018 Oct 26.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. Couban S, Benevolo G, Donnellan W, Cultrera J, Koschmieder S, Verstovsek S, Hooper G, Hertig C, Tandon M, Dimier N, Malhi V, Passamonti F.; J Hematol Oncol. 2018 Sep 24;11(1):122.
High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C, Griesshammer M.; Ann Hematol. 2019 Jan;98(1):93-100. Epub 2018 Aug 28.
Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Griesshammer M, Sadjadian P, Wille K.;"Expert Rev Hematol. 2018 Sep;11(9):697-706.
Ruxolitinib. Ajayi S, Becker H, Reinhardt H, Engelhardt M, Zeiser R, von Bubnoff N, Wäsch R.; Recent Results Cancer Res. 2018;212:119-132.
Recommendations for the diagnosis and treatment of patients with polycythaemia vera. Hatalova A, Schwarz J, Gotic M, Penka M, Hrubisko M, Kusec R, Egyed M, Griesshammer M, Podolak-Dawidziak M, Hellmann A, Klymenko S, Niculescu-Mizil E, Petrides PE, Grosicki S, Sever M, Cantoni N, Thiele J, Wolf D, Gisslinger H.; Eur J Haematol. 2018 Jul 30. [Epub ahead of print].
Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. Heidel FH, Al-Ali HK, Hirt C, Kämpfe D, Jentsch-Ullrich K, Junghanss C, Nowak R, Schwarzer A, Spohn C, Vucinic V, Hochhaus A, Lange T; Working Party Myeloproliferative Neoplasms of the East German Study Group Hematology/Oncology (OSHO). Leukemia. 2018 Sep;32(9):2085-2087. No abstract available.
JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. Edelmann B, Gupta N, Schnoeder TM, Oelschlegel AM, Shahzad K, Goldschmidt J, Philipsen L, Weinert S, Ghosh A, Saalfeld FC, Nimmagadda SC, Müller P, Braun-Dullaeus R, Mohr J, Wolleschak D, Kliche S, Amthauer H, Heidel FH, Schraven B, Isermann B, Müller AJ, Fischer T.; J Clin Invest. 2018 Oct 1;128(10):4359-4371.
Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. Harrison CN, Griesshammer M, Miller C, Masszi T, Passamonti F, Zachee P, Durrant S, Pane F, Guglielmelli P, Verstovsek S, Jones MM, Hunter DS, Sun W, Li J, Khan M, Habr D, Kiladjian JJ.; Br J Haematol. 2018 Jul;182(2):279-284. No abstract available.
Germ line predisposition to myeloid malignancies appearing in adulthood. Crysandt M, Brings K, Beier F, Thiede C, Brümmendorf TH, Jost E.; Expert Rev Hematol. 2018 Aug;11(8):625-636. Epub 2018 Jul 23.
Loss of DEP-1 (Ptprj) promotes myeloproliferative disease in FLT3-ITD acute myeloid leukemia. Kresinsky A, Bauer R, Schnöder TM, Berg T, Meyer D, Ast V, König R, Serve H, Heidel FH, Böhmer FD, Müller JP.; Haematologica. 2018 Nov;103(11):e505-e509. No abstract available.
Serum of myeloproliferative neoplasms stimulates hematopoietic stem and progenitor cells. Lubberich RK, Walenda T, Goecke TW, Strathmann K, Isfort S, Brümmendorf TH, Koschmieder S, Wagner W.; PLoS One. 2018 May 31;13(5):e0197233.
Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial. Griesshammer M, Saydam G, Palandri F, Benevolo G, Egyed M, Callum J, Devos T, Sivgin S, Guglielmelli P, Bensasson C, Khan M, Ronco JP, Passamonti F.; Ann Hematol. 2018 Sep;97(9):1591-1600.
Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, Crysandt M, Mayer K, Jonas J, Stelljes M, Badbaran A, Ayuketang Ayuk F, Triviai I, Wolf D, Wolschke C, Kröger N.; Eur J Haematol. 2018 Sep;101(3):305-317.
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. De Stefano V, Carobbio A, Di Lazzaro V, Guglielmelli P, Iurlo A, Finazzi MC, Rumi E, Cervantes F, Elli EM, Randi ML, Griesshammer M, Palandri F, Bonifacio M, Hernandez-Boluda JC, Cacciola R, Miroslava P, Carli G, Beggiato E, Ellis MH, Musolino C, Gaidano G, Rapezzi D, et al.; Blood Cancer J. 2018 Feb 28;8(3):25.
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Leukemia. 2018 May;32(5):1057-1069. Review.
Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. Heidel FH, Gale RP, Hochhaus A. Leukemia. 2018 May;32(5):1055-1056.No abstract available.
Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S, Passamonti F, Jones M, Zhen H, Li J, Gadbaw B, Perez Ronco J, Khan M, Verstovsek S. Ann Hematol. 2018 Apr;97(4):617-627. Epub 2018 Feb 2.
Oncogenic JAK2^V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R. Sci Transl Med. 2018 Feb 21;10(429).
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms. Mughal TI, Gotlib J, Mesa R, Koschmieder S, Khoury HJ, Cortes JE, Barbui T, Hehlmann R, Mauro M, Saussele S, Radich JP, Van Etten RA, Saglio G, Verstovek S, Gale RP, Abdel-Wahab O. Leuk Res. 2018 Feb 14;67:67-74. Review.
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study Birgegard G, Besses C, Griesshammer M, Gugliotta L, Harrison CN, Hamdani M, Wu J, Achenbach H, Kiladjian JJ. Haematologica. 2018 Jan;103(1):51-60.

Publikationen 2017

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Nieborowska-Skorska M, Maifrede S, Dasgupta Y, Sullivan K, Flis S, Le BV, Solecka M, Belyaeva EA, Kubovcakova L, Nawrocki M, Kirschner M, Zhao H, Prchal JT, Piwocka K, Moliterno AR, Wasik M, Koschmieder S, Green TR, Skoda RC, Skorski T. Blood. 2017 Dec 28;130(26):2848-2859.
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium. Griesshammer M, Sadjadian P. Expert Opin Pharmacother. 2017 Dec;18(18):1929-1938.
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL. Leuk Res. 2017 Dec;63:34-40.
[Thrombocytosis and thrombocytopenia - background and clinical relevance]. Wille K, Sadjadian P, Griesshammer M. Dtsch Med Wochenschr. 2017 Nov;142(23):1732-1743. Review. German.
The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, Mathias J, Komatsu N, Boothroyd RN, Spierer A, Perez Ronco J, Taylor-Stokes G, Waller J, Mesa RA. Ann Hematol. 2017 Oct;96(10):1653-1665.
JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs. Cornez I, Yajnanarayana SP, Wolf AM, Wolf D. Mol Cell Endocrinol. 2017 Aug 15;451:88-96.
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Vannucchi AM, Verstovsek S, Guglielmelli P, Griesshammer M, Burn TC, Naim A, Paranagama D, Marker M, Gadbaw B, Kiladjian JJ. Ann Hematol. 2017 Jul;96(7):1113-1120.
Hacking the stem cell niche. Lane SW, Heidel FH. Blood. 2017 Jun 1;129(22):2951-2952.
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Verstovsek S, Courby S, Griesshammer M, Mesa RA, Brachmann CB, Kawashima J, Maltzman JD, Shao L, Xin Y, Huang D, Bajel A. Leuk Res. 2017 May 30;60:11-17.
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study. Palandri F, Tiribelli M, Benevolo G, Tieghi A, Cavazzini F, Breccia M, Bergamaschi M, Sgherza N, Polverelli N, Crugnola M, Isession_id()ori A, Binotto G, Heidel FH, Buccisano F, Martino B, Latagliata R, Spinsanti M, Kallenberg L, Palumbo GA, Abruzzese E, Scaffidi L, Cuneo A, Cavo M, Vianelli N, Bonifacio M. Hematol Oncol. 2017 May 17. [Epub ahead of print]
Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. Schnöder TM, Eberhardt J, Koehler M, Bierhoff HB, Weinert S, Pandey AD, Nimmagadda SC, Wolleschak D, Jöhrens K, Fischer T, Heidel FH. J Cancer Res Clin Oncol. 2017 May;143(5):807-820.
Modelling IRF8 Deficient Human Hematopoiesis and Dendritic Cell Development with Engineered iPS Cells. Sontag S, Förster M, Qin J, Wanek P, Mitzka S, Schüler HM, Koschmieder S, Rose-John S, Seré K, Zenke M. Stem Cells. 2017 Apr;35(4):898-908.
Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature. Jennes E, Guggenberger D, Zotz R, Thompson L, Brümmendorf TH, Koschmieder S, Jost E. Clin Case Rep. 2017 Mar 30;5(5):664-670.
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Mesa R, Vannucchi AM, Yacoub A, Zachee P, Garg M, Lyons R, Koschmieder S, Rinaldi C, Byrne J, Hasan Y, Passamonti F, Verstovsek S, Hunter D, Jones MM, Zhen H, Habr D, Martino B. Br J Haematol. 2017 Jan;176(1):76-85.
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, Callum J, Vannucchi AM, Sivgin S, Bensasson C, Khan M, Mounedji N, Saydam G. Lancet Oncol. 2017 Jan;18(1):88-99.

Publikationen 2016

[(Pan-)cytopenia as first manifestation of kryptic telomeropathies in adults]. Schmitt K, Beier F, Panse J, Brümmendorf TH. Dtsch Med Wochenschr. 2016 Oct;141(21):1578-1580.
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Haematologica. 2016 Aug;101(8):926-31.
JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus. Wenzel J, van Holt N, Maier J, Vonnahme M, Bieber T, Wolf D. J Invest Dermatol. 2016 Jun;136(6):1281-3.
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. Schlenk RF*, Stegelmann F*, Reiter A, Jost E, Gattermann N, Hebart H, Waller C, Hochhaus A, Platzbecker U, Schafhausen P, Blau IW, Verbeek W, Heidel FH, Werner M, Kreipe H, Teleanu V, Benner A, Döhner H, Grießhammer M, Döhner K, *equal contribution. Leukemia. 2017 Apr;31(4):889-895.
Associations between gender, disease features and symptom burden in the MPN population: An analysis by the MPN QOL International Working Group. Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA. Haematologica. 2017 Jan;102(1):85-93.
Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. Jentsch-Ullrich K, Eberhardt J, Zeremski V, Koehler M, Wolleschak D, Heidel FH. J Cancer Res Clin Oncol. 2016 Sep;142(9):2041-9.
Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians. Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL). Ann Hematol. 2016 Sep;95(9):1399-410.
Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Al-Ali HK, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Ronco JP, Ghosh J, Martino B, Vannucchi AM. Haematologica. 2016 Sep;101(9):1065-73.
Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA. Leuk Lymphoma. 2016 Jul;57(7):1517-26.
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm. Görtzen J, Hunka LM, Vonnahme M, Praktiknjo M, Kaifie A, Fimmers R, Jansen C, Heine A, Lehmann J, Goethert JR, Gattermann N, Goekkurt E, Platzbecker U, Brossart P, Strassburg CP, Brummendorf TH, Koschmieder S, Wolf D, Trebicka J. Medicine (Baltimore). 2016 May;95(20):e3355.
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. Han L, Schubert C, Köhler J, Schemionek M, Isfort S, Brümmendorf TH, Koschmieder S, Chatain N. J Hematol Oncol. 2016 May 13;9(1):45.
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Haematologica. 2016 Aug;101(8):926-31.
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ. Haematologica. 2016 Jul;101(7):821-9.
Get a grip on immune cells by inhibiting JAKs. Schönberg K, Rudolph J, Yajnanarayana SP, Wolf D. Oncoimmunology. 2015 Aug 12;5(2):e1071009.
[Leukemia research in Germany: the Competence Network Acute and Chronic Leukemias]. Kossak-Roth U, Saußele S, Aul C, Büchner T, Döhner H, Dugas M, Ehninger G, Ganser A, Giagounidis A, Gökbuget N, Griesshammer M, Hasford J, Heuser M, Hiddemann W, Hochhaus A, Hoelzer D, Niederwieser D, Reiter A, Röllig C, Hehlmann R. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016 Apr;59(4):444-53.
Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR. Waterhouse M, Follo M, Pfeifer D, von Bubnoff N, Duyster J, Bertz H, Finke J. Ann Hematol. 2016 Apr;95(5):739-44.
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, Bergmann F, Schilling K, Brümmendorf TH, Petrides PE, Tiede A, Matzdorff A, Griesshammer M, Riess H, Koschmieder S. Ann Hematol. 2016 Apr;95(5):707-18.
STAT1 activation in association with JAK2 exon 12 mutations. Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR. Haematologica. 2016 Jan;101(1):e15-9.
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy. Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H, Jones MM, Parasuraman S, Li J, Côté I, Habr D, Vannucchi AM. Eur J Haematol. 2016 Aug;97(2):192-200.
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. J Clin Oncol. 2016 Jan 10;34(2):151-9.
Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo. Ebert C, Perner F, Wolleschak D, Schnöder TM, Fischer T, Heidel FH. Haematologica. 2016 Mar;101(3):e81-5. No abstract available.